Geum.ru

Н. А. Корнетов нии психического здоровья Томского научного центра со рамн, Томск

Вид материалаДокументы
Подобный материал:
1   2   3   4   5   6   7

Литература



1. Вовин Р.Я., Иванов М. В., Мазо Г.Е. с соавт. Сравнительная эффективность применения серотонинергических антидепрессантов в лечении депрессий // Социальная и клиническая психиатрия. –1995.-№1. – С.72-79.

2. Информация о лекарственных средствах для специалистов здравоохранения / Под ред. М.Д. Машковского. - М:РЦ «Фарммединфо»,1996.- 255-258.

3. Каспер С. Обоснование длительной терапии антидепрессантами // Социальная и клиническая психиатрия. – 1995.-№1.- С.80-92.

4. Корнетов Н.А. Клиническая антропология: теоретический подход и основные принципы // Актуальные вопросы медицинской и клинической антропологии. – Томск, 1991.- C. 41-47

5. Корнетов Н.А. «Большая пятерка» селективных серотонинергических антидепрессантов: новые стратегии терапии и превенции депрессивных расстройств // Реабилитация психически больных. – Томск. –1998 (в печати)

6. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб: Мединформ агентство.-1995,568 с.

7. Мосолов С.Н. Основы психофармакологии – М.: Восток. – 1996. – 288 с.

8. Никитюк Б.А., Корнетов Н.А. Интегративная биомедицинская антропология. – Тосмк: Изд. Томского ун-та. –1988. – 182 с.

9. О совершенствовании лекарственного обеспечения населения Российской Федерации.- МЗРФ,М., Приказ №17,27 янв.,1998.-19с.

10. Aberg-Wistedt The antidepresant effects of 5-HT uptake ingibitors // Brit. J. Psychiatry.- 1989. – Vol. 155.-Suppl.8. – P. 32-40.

11. Aguglia E., Casacchia M., Cassano G.B. et al. Double-blind study of the efficacy and safety of sertralin versus fluoxetine in major depression // Int. Clin. Psychofarmacol. – 1993.- Vol. 8.- P. 197-202.

12. Alderman J., Greenblat D.J., Allison J et al. Desipramin pharmacokinetics with the serotonin reuptake ingibitors, paroxetine or sertraline // Presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington DC, USA, 17 June-1July 1994.

13. Alderman J., Greenblat D.J., Allison J et al. Desipramin pharmacokinetics with the serotonin reuptake ingibitors (SSRIs), paroxetine or sertraline // Neuropsychopharmacology.- 1994.-Vol. 10. – Suppl. 3/part 2. – 263S.

14. American Psychiatric Association. Practice guideline for major depressive disorder in adults // Am. J. Psychiatry. – 1993. – Vol. 150. –N. 4 - P. 1-23.

15. Amin M., Lehman., Mirmiran J. A double-blind, placebo controlled dose-finding study with sertralin // Psychopharmacol. Bull.-1989.- Vol.25.-P. 164-167.

16. Apseloff G., Wilner K.D. von Deutsch D.A. et al. Sertraline does not alter steady-state concentration or renal clearanse of lithium in healthy volunteers // J. Clin. Pharmacol. – 1992.- Vol. 32.- P. 643-646.

17. Apseloff G., Wilner K.D. Gerber N. et al. Effect of sertraline on the protein binding of warfarin // Clin. Pharmacokinetic. – 1997.- Vol. 32.-Suppl.1.- P. 37-42.

18. Baldwin D., Bullok T., Montgomery D. et al. 5-HT reuptake ingibitors, tricyclic antidepressants and suicidal behavior // Intern. Clin. Psychopharmacol.-1991.- Vol.6.-Suppl.3.- P. 49-55.

19. Bargstrom R.F., Lamberger L., Farrid N.A. et al. Clinical pharmacology pharmacokinetic of floxetine: a review // Brit. J. Psychiatry. – 1988. – Vol. 153. – Suppl. 3. – P. 47-50.

20. Barros J., Asnis G. An interaction between of the sertraline and desipramine (Letter) // Am. J. Psychiatry. - 1993. – Vol. 150. – P. 300.

21. Barton S.W. Symptoms as predictors of response in depression // Journal of Psychopharmacol.-1993.- Vol.7. –Suppl. 1 - P. 135-138.

22. Baumann P., Bertschy G. Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRI) with other psychotropic drugs // Nord. J. Psychiatr.-1993.-Vol.47.-(Suppl.30).-P. 13-19.

23. Bennie E.H. Double-blind study of sertralin and fluoxetine in outpatients with major depression // Presented at the 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, 6-12 June,1993.

24. Bennie E., Mullin J.M., Martindale J.J. et al. A double-blind multicenter trial comparing of sertralin and fluoxetine in outpatients with maior depression // J. Clinic. Psychiatry. – 1995. – Vol. 56.- P. 229-237.

25. Bertilsson L., Henthorn T.K., Sans E. et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S –mephenitoin but not debrisoquine hydroxilation phenotype // Clin. Pharmacol. Ther. – 1989. – Vol. 45. – P. 348-355.

26. Brosen K., Skieblo E. Fluoxetin and norfluoxetin are potent ingibitors of P4502D6: the source of the spateine/debrisoquine oxidation polymorphism (Letter)// Br. J. Clin. Pharmacol. –1992.-Vol.34.-P. 256-261.

27. Brosen K., Skjeblo E., Rasmussen B.B. et al. Fluvoxamin is a potent inhibitor of citochrome P4501A2 // Biochem. Pharmacol.-1993.- Vol.45.-N6.-P. 1211-1214.

28. Brown W. A. An investigation to determine the relationship between plasma levels of the 5-HT uptake ingibitor sertralin and efficacy /side effects in outpatients with major depression // Poster presented at ACNP, San Juan, Puerto Rico, December, 9-13, 1991.

29. Burke M.J., Harvey A.T., Preskorn S.N. Pharmacokinetics of the newer antidepressants (Letter) // Am. J. Med. – 1996. – Vol. 100. – P.119-120.

30. Byerly W.F., McConnell E. J., McCabe R.T. et al. Chronic administration of sertraline, a selective serotonin re-uptake inhibitor, decreased and density of B-adrenergic receptors in rat frontoparietal cortex // Brain Res. –1987. – Vol. 421. – P. 377-381.

31. Callaham M., Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management // Ann. Emerg. Med.- 1985.-Vol.14.-P.1-9.

32. Casey D.E. Striking a balance between safety and efficacy: experiense with the SSRI // Intern. Clin. Psychopharmacol.-1994.- Vol.9.-Suppl.3.- P. 5-12.

33. Clayton P.J. The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression // J. Clinic. Psychiatry. – 1990. – Vol. 51.- Suppl. 11. - P. 28-33.

34. Clayton P.J., Grove W. M., Coryell W et al. Follow-up and family study of anxious depression // Am. J. Psychiatry. – 1991. – Vol. 148. - P. 1512-1517.

35. Clayton P.J. Depression and anxiety: diagnosis and treatment of coxiting disorders / Depression in United States: underrecognized and undertreated? M.B. Keller (Ed.). – Minn: McGraw-Hill Healthcare Publ. –1994. – P.21-26.

36. Coffey D.J., Jenkin L.R., Coffey A.K. et al. Sertralin versus amitriptyline versus placebo: effects on cognitive and motor function in the elderly // Presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington DC, USA, 17 June-1 July 1994.

37.Coffey D.J., Richter E.M. A double-blind comparison of sertralin and norttriptylin in the treatment of depressed geriartric outpatients // European Neuropsychopharmacology.- 1994.-Vol. 4.-P.333-334.

38. Cohn C.K., Shrivastava R., Mendels J et al. Double-blind multicenter, comparison of sertralin and amitriptyline in elderly depressed patients // J. Clinic. Psychiatry. – 1990. – Vol. 51.- P. 28-33.

39. Crewe H.K., Lennard M.S., Tucker G.T. et al. The effect of selective serotonin reuptake ingibitors on citochrom P4502D6 (CYP2D6) activity in human liver microsomes // Br. J. Clin. Psychofarmacol. – 1992.- Vol. 34.- P. 262-265.

40. Physicians desk reference/ 49 Ed. –1995.-P.2111

41. Dingemanse J. An update of recent moclobemide interaction date // Int. Clin. Psychofarmacol. – 1993.- Vol. 7.- P. 167-180.

42. Doogan D.P. Toleration and safety of sertraline: experience worldwide // Int. Clin. Psychofarmacol. – 1991.- Vol. 6.- P. 47-56.

43. Doogan D.P., Caillard V. Sertraline, a new antidepressant // J. Clinic. Psychiatry. – 1988. – Vol. 49.-Suppl.8.- P. 46-51.

44. Doogan D.P., Caillard V. Sertraline in the prevention of depression // Brit. J. Psychiatry. – 1992. – Vol. 160.- P. 217-222.

45. Doogan D.P., Langdon C.G. A double-blind placebo controlled comparison of sertralin and dothiepin in the treatment of major depression in general practice // Intern. Clin. Psychopharmacol.-1994.- Vol.9.-P. 95-100.

46. Edwards R.A., Newburn G. Sertraline versus clomipramine in major depression: a single blind trial // Presented at 29th Congress of the Royal Australian and New Zealand College of Psychiatrists, Tasmania,15-19 May, 1994.

47. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine // J. Clin. Psychopharmacol.-1996.- Vol.16. Suppl. 2. – 37S-53S.

48. Fabre L.F. A double-blind multicenter study comparing the safety and efficacy of sertralin with placebo in major depression // Presented at 5th World Congress of biology psychiatry.- Italy, Florence, 9-14 June, 1991.

49. Fabre L.F., Abuzzahab F.S., Amin M. et al. Sertralin safety and efficacy in major depression // Biological Psychiatry.-1995.-Vol.38.- P.592-602.

50. Fisch C., Knoebel S., The effects of sertraline on the electrocardiogram is non-elderly and elderly patients with major depression // Presented at 5th Congress of the International Psychogeriartric Ass., Rome, Italy, 18-23 August, 1991.

51. Fonteine R et al. The efficacy and safety of sertralin versus imipramin in outpatients with major depression: a six month double-blind, parallel multicenter study // Poster presented at the IV Collegium Intern. Neuropsychopharmacol., Monte Carlo, Monaco, 6-9 October,1991.

52. Fonteine R et al. The efficacy and safety of sertralin versus imipramin in outpatients with major depression: a six month double-blind, parallel multicenter study // J. Europ. Col. Psychopharmacol.- 1991.- Vol. 1. P.447.

53. Forster P.L., Dewland P.M., Muirhead D. et al. The effects of sertraline on the plasma concentration and renal clearens of the digoxin // Biol. Psych. – 1991. – Vol. 29. – P.355.

54. Gardner M.J., Ronfeld R.A.,, Wilner K.D. et al. The effects of sertraline on the pharmacokinetics of diazepam in healthy volunteers // Biol. Psych.- 1991.-Vol.29.- P. 354.

55. Gardner M.J., Baris B.A., Wilner K.D. et al. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers // Clinic. Pharmacokinet. – 1997. – Vol. 32.-Suppl.1.- P.43-49.

56. Glassman A.N. Preud’homme X.A. Review of the cardiovascular effects of heterocyclic antidepressants // J. Clinic. Psychiatry. – 1993a. – Vol. 54.-Suppl.2.- P. 16-22.

57. Glassman A.N., Roose S.P., Bigger J.T. The safety of tricyclic antidepressants in cardiac patients: risk benefit recosidered // JAMA. – 1993b. –Vol. 269. – P. 2673-2675.

58. Goethe J. W., Szarek B.L., Cook W.L. A comparison of adequately vs. inadequately treated depressed patients // J. Nerv. Ment. Disease. – 1988. – Vol. 176. – P. 465-470.

59. Gram L.E. Hansen M.G.J., Sindrup S.H. et al. Citalopram: interaction studies with levomeprazine, imipramine, and lithium // Ther. Drug. Monit.-1993.- Vol.15.-P.18-24.

60. Greenberg P.F., Stiglin L.E., Finkelstein S.N. et al. The economic burden of depression in 1990 // J. Clinic. Psychiatry. – 1993. – Vol. 54.- P. 405-418.

61. Guthrie S.K. Sertraline: a new specific serotonin reupteike blocker // DICP Ann. Pharmacoter.- 1991.-Vol.25. P. 952.

62. Hamilton M. A rating scale for depression // J. Neurol. Neurosurg. Psychiat. – 1960.-Vol.23.-P.278-296.

63. Harvey A.T., Preskorn S.H. Interactions serotonin reuptake inhibitors with triciclic antidepressants // Arch. Gen. Psychiatry. – 1995. – Vol. 52.- P.783-784.

64. Harvey A.T., Preskorn S.H. Citochrome P450 enzimes: interpretation of their interactions with SSIs. Pt.I // J. Clin. Psychopharmacol.-1996a.- Vol.16.-P. 273-285.

65. Harvey A.T., Preskorn S.H. Citochrome P450 enzimes: interpretation of their interactions with SSIs. Pt.II // J. Clin. Psychopharmacol.-1996b.- Vol.16.-P. 345-355.

66. Heym J., Koe B.K. Pharmacology of sertraline: a review // J. Clinic. Psychiatry. – 1988. – Vol. 49.- P. 40-45.

67. Heym J., Reinolds L.S. Chronic administration of sertraline desensitizes serotonin autoreceptors // Society of Neuroscience abstracts. – 1989. – Vol.15. – P.46.

68. Hindmarch I., Bhatti J.Z. Psychopharmacological effects of sertraline in normalhealthy volunteers // Eur. J. Clin. Pharmacol. 1988.- Vol.35.-P. 221-223.

69. Hindmarch I., Shilingford J., Shilingford C. The effects of sertraline on psychomotor performance in elderly volunteers // J. Clinic. Psychiatry. – 1990. – Vol. 51.-Suppl.B.- P. 34-36.

70.Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and hender on the activity of human hepatic CYP3A // Biochem. Pharmacol. –1992. –Vol. 44. – P.275-283.

71. Hyttel J. Comparative pharmacology of selective serotonin reuptake ingibitors (SSRIs) // Nord. J. Psychiat.-1993.- Vol. 47.-Suppl.30.-P.5-12.

72. Jann M.W., Jenike M.A., Lieberman S.N. The new psychopharmaceuicals // Patient Care. – 1994.-Vol. 30 (January).-P. 47-57.

73. Jann M.W., Carson S.W., Grimsley S.R. et al. Effects of sertraline upon imipramine pharmacodynamics // Clin. Pharmacol. Ther. 1995.- Vol.57.-P. 207-211.

74. Jenkyn L.R. et al. Effects of sertralin versus amitriptyline on cognitive and motor functions in the elderly // Amer. Ceriartr. Ass., Congress, November, 1992.

75. Keller M.B. Undertreatment of major depression // Psychopharmacology Bull. – 1988. – Vol. 24. – P. 75-80.

76. Kline N.A., Dow B.M., Brown S.A. et al. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder // Presented at the 146th Annual Meeting of the Am. Psychiatry Ass., San Francisco, USA, 20-26 May, 1993.

77.Koe B. K., Weissman A., Welch W.M., Browne R.G. Sertraline 1S, 4S-N-methyl-4-(3,4-diclorophenil) –1,2,3,4- tetrahidro-1-naphtilamin, a new uptake inhibitor with selectivity for serotonin // J. Pharmacol. Exp. Ther.-1983a.-Vol. 226.- P. 686-700.

78. Koe B. K., Weissman A., Welch W.M. at al. Sertraline, a new selective inhibitor of serotonin upteike // Psychopharmacol Bull.- 1983b.-Vol.19. P. 687-691.

79. Koe B. K., Vinik F.J. Adaptive changes in central nervous system receptor systems // Ann. Rep. Med. Chem. – 1984. – Vol. 19. –P. 41-50.

80. Koe B. K., Koch S. W., Lebel L.A. et al. Sertraline, a selective inhibitor of serotonin upteike, indduces subsensitivity of beta-adrenoreceptor system of rat brain // Eur. J. Pharmacol. –1987. – Vol. 141. – P.187-194.

81.Koe B. K. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin re-uptake // J. Clinic. Psychiatry. – 1990. – Vol. 51.-Suppl.B.12.- P. 3-17.

82. Kupfer D.J. Long-term treatment of depression // J. Clinic. Psychiatry. – 1991. – Vol. 52.-Suppl.B.12.- P. 28-34.

83. Kupfer D.J. Management of recurrent depression // J. Clinic. Psychiatry. – 1993. – Vol. 54.-Suppl.2.- P. 29-33.

84. Kupfer. D.J., Freedman D.X. Treatment for depression: “standart” clinical practice as an unexamined topic (comment) // Arch. of General Psychiatry. – 1986. – Vol. 43. –P. 509-511.

85. Kurtz D., Bergstorm R., Goldberg M. et al. Drug interactions between sertraline and desipramine or imipramine (abstract) // J. Clin. Pharmacol. – 1994.-Vol.34.-P.1009-1033.

86. Lamy P.P., Salzman C., Nevis Olesen J. Drug prescribing patterns, risks, and complaince guidelines // Clinical Geriatric Psychopharmacology. 2 Edn./ Ed. C. Salman. – Baltimore: Williams and Wilkins. – 1992. –P. 15-370.

87. Lane R.M. // Мanaging depression in general practic // Brit. Med. J. –1993a.- Vol.306.- P. 272-273.

88. Lane R.M. Antidepressant therapy in the physically ill: a therapeutic opportunity for the selective 5-HT reuptake inhibitors? // J. Psychopharmacol.-1993b.- Vol.7.-Suppl.2.- P. 112-118.

89.Lane R.M. Potential pharmacokinetics interactions of selective serotonin reuptake ingibitors with other drugs // Intern. Clin. Psychopharmacol.-1996.- Vol.11.- Suppl.5 - P. 31-61.

90. Lane R.M., Sweeney M., Henri J. Pharmacotherapy of the depressed patients with cardiovascular or cerebrovascular illness // Brit. J. Clin. Practic.-1994.-Vol.48.-P. 256-262.

91. Latimer P.R., Ravindran A.V. Bernatchez J-P et al. A six month comparison of toleration and efficacy of sertraline and fluoxetine of major depression // Poster presented at XXth Collegium Intern. Neuropsychopharmacol., Melbourne, Australia,1996.

92. Lemberger L., Row H., Bosomworth et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam // Clin. Pharmacol. Ther. – 1988.- Vol. 43. –P. 412-419.

93. Liebowitz M.R. Depression with anxiety and atypical depression // J. Clinic. Psychiatry. – 1993. – Vol. 54.-Suppl.2.- P.10-14.

94. Llerena A., Edman G., Gobaleda J. et al. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6 // Acta Psychiatr. Scand. – 1993. – Vol. 87. – P. 23-28.

95. Lydiard T., Anton R.E., Cunningham T. Interactions between sertraline and tricyclic antidepressants // Am. J. Psychiatry. - 1993. – Vol. 150. – P. 1125-1126.

96. Mardoch D., McTavich D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compylsive disorder // Drugs. – 1992.-Vol. 44.-P. 604-624.

97. Mattila M.J., Saarialho-Kere U., Mattila M. Acute effects of sertraline, amitriptyline, and placebo on psychomotor performance on healthy subjects over 50 years of age // J. Clinic. Psychiatry. – 1988. – Vol. 49.-Suppl.- P. 52-58.

98. Meltzer H.Y., Lowy M.T. The serotonin hypothesis of depression // Clin. Psychopharmacology: the third generation of progress / Ed. H.Y. Meltzer. – New York: Raven Press. – 1987.- Vol. 52. – P. 513-526.

99. Mendels J. The acute and long-term treatment of major depression // Intern. Clin. Psychopharmacol.-1991.- Vol.7.-Supp2.- P. 21-29.

100. Mendels J., Camera A. Sertralin treatment for premature ejaculation // Neuropsychopharmacology.- 1994.-Vol. 10.-P.189.

101. Mertens C., Bartholome F., Cosyns P. et al. A controlled comparison of sertralin and fluoxetine in acute and continuation treatment of major depression // Presented at 148th Am. Psychiatry Ass., Miami, USA< 20-26 May, 1995.

102. McGrath P.J. Pleminary information about sertraline (Zoloft) – a new, highly, selective, serotonin reuptake inhibitor // Curr. Affect ILL. -1992. – Vol.11. – P. 5-14.

103. Montamat S.C., Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly // Clin. Geriatr. Med. – 1992. –Vol. 8. – P. 143-158.

104. Montano B.C. Recognition and treatment of depression in a Primary Care Setting // J. Clinic. Psychiatry. – 1994. – Vol. 55.-Suppl.12.- P.18-34.

105. Montgomery S. A. Progress on long-term management - report of an ICANP consensus // Presented at VIIth European College of Neuropsychopharmacology, Jerusalem, Israel,16-21 October, 1994.

106. Montgomery S. Serotonin, sertraline and depression // J. Psychopharmacol.- 1995.-Vol.9.- Suppl.2 - P. 179-184.

107. Montgomery S. A., Asberg M. A new depression scale design to be sensetive to change // Brit. J. Psychiatry.- 1979. – Vol. 134. – P. 382-389.

108. Montgomery S.A., Doogan D.P., Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline // Intern. Clin. Psychopharmacol.-1991.- Vol.6.-Suppl.2.- P. 37-46.

109. Moon C.A.L., Wood K., Lane R.M., Jago W. Sertraline and clomipramine in mixed anxiety depression // Presented at the British Ass. Psychopharmacol., Cambrige, UK, July 25-28, 1993.

110.Moon C.A.L., Jago W., Wood K et al. A double-blind comparison of sertralin and clomipramine in the treatment of major depression disorders and associated anxiety in general practice// Poster presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington DC, USA, 17 June-1July 1994.

111. Moon C.A.L., Jago W., Wood K et al. A double-blind comparison of sertralin and clomipramine in the treatment of major depression disorders and associated anxiety in general practice// J. Psychopharmacol.-1994.- Vol.8.-Suppl.3.- P. 171-176.

112. Nebert D.W., Nelson D.R., Adesnic M. et al. The P-450 superfamily: update listing of all genes and recommended nomenclature for the chrosomal loci // DNA Seq. -1989.-Vol.8.-P.1-13.

113. Nebert D.W., Nelson D.R., Coon M.J. et al. The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature // DNA Cell. Biol. -1991.-Vol.10.-P.1-14.

114. Nelson D.R., Kamataki T., Waxman D.J. et al. The P-450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature // DNA Cell Biol.-1993.-Vol.12.-P.1-51.

115. Nemeroff Ch. B. Evolutionary trends in the pharmacotherapeutic management of depression // J. Clinic. Psychiatry. – 1994. – Vol. 55.-Suppl.12.- P.3-15 .

116. Newhous P.A., Richter E.M. SSRis in depressed elderly: a double-blind comparison of sertralin and fluoxetine in depressed geriatric patients // Presented at VIIth European College of Neuropsychopharmacology, Jerusalem, Israel,16-21 October, 1994a.

117. Newhous P.A., Richter E.M. SSRis in depressed elderly: a double-blind comparison of sertralin and fluoxetine in depressed geriatric outpatients // Poster presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington DC, USA, 17 June-1July 1994b.

118. Olie J.P., Gunn K.P., Katz E Sertraline: Efficacy and toleration in major depression // Presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington DC, USA, 27 June-1 July 1994.

119. Otton S.V., Ball., S.E., Cheung S.W. et al. Comparative inhibition of the polimorphic enzim CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors // Clin. Pharmacol. Ther. –1994. – Vol. 55. – P.141.

120. Quitkin F.M., Burnside R., Yurkewiicz L. Positive pattern analysis results in sertraline depression trails // Presented at XVIIIth CINP, Nice, France, June 28- July 2, 1992.

121. Peck C.C., Temple R., Collins J.M. Understanding consequences of concurrent therapies // J. Am. Med. Ass. –1993. Vol. 269. – P. 1550-1552.

122. Peroutka S. J., Sleight A.J., McCarthy B.G. et al. The clinical utility of pharmacological agents that act as serotonin receptor // Journal of Neuropsychiatry. –Vol.1. – P. 253-262.

123. Perucca E., Gatti G., Cippola G et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers // Clin. Pharmacol. Ther. –1994.- Vol. 56.- P.471-476.

124. Pollock B.G., Perel J.M. Tricyclic antidepressants: contemporary issues for therapeutic practice // Can. J. Psychiatry – 1989. – Vol. 32. – P. 609-617.

125. Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment // J. Clinic. Psychiatry. – 1993. – Vol. 54.-Suppl.9.- P.14-34.

126. Preskorn S.H. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline // Intern. Clin. Psychopharmacol.-1994.- Vol.9.-Suppl.3.- P. 3-19.

127. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazadone, paroxetine, sertraline and venlafaxine // J. Clinic. Psychiatry. – 1995. – Vol. 56.-Suppl.6.- P.12-21.

128. Preskorn S.H. Clinically relevant Pharmacology of selective serotonin re uptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism // Clin. Pharmacokinet.- 1997.- Vol. 32.- Suppl.1.- P. 1-21.

129. Preskorn S.H., von Moltter L., Alderman J. et al. In vitro and in vivo evaluation of the potencial for desipramine interaction with fluoxetine or sertralin // Presented at the 146th Annual Meeting of the Am. Psychiatry Ass., San Francisco, USA, 20-26 May, 1993.

130. Preskorn S.H., Alderman J., Chung M. et al. Pharmacokinetics of desipramine coadministered with sertralin or fluoxetine // J. Clin. Psychopharmacol.- 1994.-Vol.14.- N 2.- P. 90-98.

131. Rasmussen B.B., Maenpaa J., Pelconen O et al. Selective serotonin reuptake ingibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine // Br. J. Clin. Pharmacology. – 1995. – Vol.39. – P.151-159.

132. Regier D.A., Hirschfeld R.M.A., Goodwin F.K. et al. The NIMN depression awereness, recognition, and treatment programm: structure, aims, and scientific basis// Am. J Psychiatry. - 1988. – Vol. 145. – P. 1351-1357.

133. Reimherr F.W., Chouinard G., Cohn C.K. et al. Antidepressant effcacy of sertralin: a double-blind, placebo and amitriptyline-controlleed multicenter comparison study in outpatients with major depression // J. Clinic. Psychiatry. – 1990. – Vol. 51.-Suppl.B.12.- P. 9-12.

134. Revicki D.A., Turner R.R., Martindale J.J. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment // Quality of life Res.-1992.- Vol.1. - P. 257-266.

135. Reynolds C.F., Kupfer D.J. Sleep research in affective ilness: state of the art circa 1987 // Sleep. – 1987. – Vol. 10. – P. 199-215.

136. Richelson E. Synaptic pharmacology of antidepressant: an update // McLean Hospital Journal.-1988.-Vol.13.- P.67-88.

137. Rickels K., Schweizer E. Clinical overview of serotonin reaptake inhibitors // J. Clinic. Psychiatry. – 1990. – Vol. 51.-Suppl.B.- P. 14-20.

138. Robins E. The final month: A study of 134 persons who committed suicide. – Ney York: Oxford University Press. –198 1.-P. 424.

139. Robins L.N., Kullok P.A. Epidemiological study in suicide. Review of Psychiatry. – Washington DS: Am. Psychiatric Press.- 1988.-Vol. 7. –289-306.

140. Ronfeld R. A., Tremaine L. M., Wilner K.D. Pharmacokinetics of sertralin and N-demethyl metabolite in elderly and young male and female volunteers // Clin. Pharmacokinet.- 1997.- Vol. 32.- Suppl.1.- P. 22-30.

141.Schatzberg A.F. Dosing strategies for antidepressant agents // J. Clinic. Psychiatry. – 1991. – Vol. 52.-Suppl.5.- P. 14-20.

142. Sechter. D., Troy S., Rioux P. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients // Eur. Neuropsycholopharmacol.- 1996.-Vol.6.-Suppl.3. - P.124

143. Skjeblo E., Brosen K. Inhibitors of imipramine metabolism by human liver microsomes // Br. J. Clin. Pharmacol. – 1992. – Vol. 34. – P. 256-261.

144. Spina E., Pollicino A.M., Avenoso A et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects // Ther. Drug Monit. –1993. – Vol. 15. – P. 247.

145. Tompson C. Managment of depression in real-life settings: knowledge gained from large-scale clinical trials // Intern. Clin. Psychopharmacol.-1994a.- Vol.9.-Suppl.3.- P. 21-25.

146. Tompson C., Lane R. Sertraline 50 mg: optimal daily dose in depression // Poster presented at XIXth Collegium Intern. Neuropsychopharmacol., Washington, USA, 27 June-1 July 1994b.

147. Tulloch I.F., Johnson A.M. The pharmacologic profil of paroxetin, a new selective serotonin reuptake ingibitor // J. Clinic. Psychiatry. – 1992. – Vol. 53.-Suppl.2.- P. 7-12.

148. Turner R. Quality of life: experience with sertraline // Intern. Clin. Psychopharmacol.-1994.- Vol.9.-Suppl.3.- P. 27-31.

149. Ustun T.B., Sartorius N. Eds. Menntal illnes in general health care: an international study. – New York : John Wiley & Sons. – 1995.

150. Wamsley J.K., McCabe R.T., McConnel E.J. Sertraline, an antidepressant which inhibits serotonin uptake specifically down regulates beta1 receptors // Psychopharmacology.-1988.- Vol.96.-Suppl.B.- P. 270.

151. Ware J.C., Morewitz J. Diagnosis and treatment of insomnia and depression // J. Clinic. Psychiatry. – 1991. – Vol. 52.-Suppl.6.- P. 55-61.

152. Wells K.B., Stewart A., Hays R.D. et al. The function and well-being of depressed patients: results from the medical outcomes Study // J. Amer. Medical Ass. – 1989. – Vol. 262. – P. 914-919.

153. Warrington S.J. Clinical implications of the pharmacology of sertraline reaptake inhibitors // Int. Clin. Psychopharmacol.- 1992.-Vol.7. Suppl.2- P. 13-21.

154. Wesnes K.A., Forster P.L., Grimwood V. Studies of the potential cognitive interactions between sertraline and haloperidol, carbamazepine and phenytoin in volunteers // Presented at the 34th Annual Meeting of the new clinical drug evaluation unit, Marco, Island, Florida, May 31- June 3, 1994.

155. Wilner K.D., Lazar J.D., Apseloff G. et al. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers // Biol. Psych.- 1991.-Vol.29.- P. 354.

156. Winokur A., Sewitch D.E., Phillips J. L. et al. Sleep architecture and mood effects of sertraline in outpatients with mayor depression: a pleminary report // Biol. Psych.- 1991.-Vol.29.- P. 162-163.

157. WHO Mental Health Colloborating Centres. Pharmacotherapy of depressive disorders: a consensus statement // J. Affective Disorders. – 1989. – Vol. 17. – P. 197-198.

158. Van Moffaert M., Bartholome F., Cosyns P. et al. A controlled comparison of sertraline and fluoxetine in the acute and continuation treatment of major depression // Hum. Psycholopharmacol.- 1995.-Vol.10.- P. 393-405.

159. Von Moltke L.L., Greenblatt D.J., Shader R.I. Clinical pharmacokinetics of antidepressants in the elderly: therapeutic implications // Clin. Pharmacokinet.- 1993.- Vol. 24.- P. 141-160.

160. Ziegler M.G., Wilner K.D., Henry E.B. et al. Effects of sertraline on the betaadrenergic blooking activity of atenolol in healthy volunteers // Presented at XVIIIth CINP, Nice, France, June 28- July 2, 1992.

161. Zimmer A.W., Davie C.C., Fowles S.E. et al. Conducting clinical research in geriartic population // Ann. Intern. Med. – 1985. – Vol. 103. – P. 276-283.


Copyright


© Н.А.Корнетов

© Сибирский вестник психиатрии и наркологии, 1988